Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- General Virology
-
46 min
1. Principles of virology- Prof. Vincent Racaniello
-
36 min
2. The type I interferon system and viruses- Dr. Adolfo Garcia-Sastre
-
45 min
3. Immune responses to viruses- Prof. Paul Klenerman
- Emerging Pathogens
-
29 min
4. Emerging or newly discovered viral causes of acute lower respiratory tract infections worldwide- Dr. Marietjie Venter
- Mrs. Orienka Hellferscee
-
37 min
5. Emerging respiratory viruses - discoveries between 2001 and 2005- Prof. Ron Fouchier
-
28 min
6. Usage of vaccines and therapeutics in public health emergencies 1- Prof. Gary Kobinger
-
39 min
7. Usage of vaccines and therapeutics in public health emergencies 2- Prof. Gary Kobinger
-
50 min
8. Influenza virus pandemics: past and future- Prof. Peter Palese
-
63 min
9. SARS-CoV and other emerging coronaviruses- Prof. Ralph Baric
-
36 min
10. Dengue, Zika and Chickungunya viruses- Prof. Ana Fernandez-Sesma
-
43 min
11. Paramyxoviruses: biology & pathogenesis- Prof. Benhur Lee
-
36 min
12. Antiviral drugs (non-HIV)- Prof. Megan Shaw
-
41 min
13. Biodefense challenges- Dr. David Franz
- Important Pathogens and their Diseases
-
38 min
14. Natural history and pathogenesis of herpes virus infections- Prof. Richard Whitley
-
40 min
15. Cytomegalovirus biology- Prof. Domenico Tortorella
-
46 min
16. Hepatitis C virus: discovery, cure and protection- Dr. Matthew Evans
-
32 min
17. Fundamentals of HIV biology- Prof. Viviana Simon
-
44 min
18. Measles- Prof. Diane E. Griffin
-
42 min
19. Monkeypox virus, vaccines, and therapeutics- Prof. Rachel Roper
- New Frontiers
-
45 min
-
55 min
-
30 min
22. Viruses as anticancer weapons- Prof. Roberto Cattaneo
-
48 min
23. Novel approaches to diagnosis of viral infections- Prof. W. Ian Lipkin
-
36 min
24. The Global Virus Network: collaboration to address pandemic and regional threats- Prof. Sten H. Vermund
-
31 min
25. Elite controllers of HIV: from discovery to future therapies- Prof. Bruce Walker
- Archived Lectures *These may not cover the latest advances in the field
-
43 min
26. Principles of virology I- Prof. Richard Condit
-
43 min
27. Principles of virology II- Prof. Richard Condit
-
36 min
28. Complex DNA viruses: herpes virus- Dr. John Blaho
-
38 min
29. Adeno-associated viruses (AAV)- Prof. Kenneth Berns
-
60 min
30. Poxviruses: smallpox (variola), vaccinia and monkeypox- Prof. Paula Traktman
-
26 min
31. Can HPV testing be the sole primary cervical screening modality?- Prof. Jack Cuzick
-
29 min
32. From viruses to oncolytics- Prof. Roberto Cattaneo
-
38 min
33. Non HIV antivirals- Prof. Mary Klotman
-
42 min
34. Gastroenteritis viruses- Prof. Mary Estes
-
46 min
35. Biodefense challenges- Dr. Connie Schmaljohn
-
32 min
-
49 min
37. The past, present and future of vaccination- Prof. Stanley Plotkin
-
41 min
38. Filoviruses- Dr. Christopher Basler
-
41 min
39. Bunyaviruses- Prof. Richard Elliott
-
41 min
40. The immunobiology of HIV- Prof. Norman Letvin
-
59 min
41. Hepatitis C and HCV- Prof. Stanley Lemon
Printable Handouts
Navigable Slide Index
- Introduction
- Nucleoside analogues: first line herpes antivirals
- Phosphorylation of acyclic nucleoside analogues
- Acyclovir (zovirax)
- Mechanism of action of acyclovir
- Pharmacokinetics of acyclovir and valacyclovir
- Toxicities of acyclovir and valacyclovir
- Antiviral resistance
- Clinical application of acyclovir
- Clinical application continued
- Herpes gingivostomatitis/labialis
- First episode or recurrent genital herpes
- Severe HSV disease: IV high-dose acyclovir
- Varicella zoster
- Other anti-HSV drugs
- Anti-CMV drugs: ganciclovir and valganciclovir
- Mechanism and pharmacokinetics of ganciclovir
- Toxicities of ganciclovir
- Ganciclovir resistance
- Clinical indications for ganciclovir
- CMV retinitis in AIDS
- Alternative anti-herpes drugs: foscarnet (foscavir)
- Foscarnet: pharmacokinetics and toxicities
- Foscarnet: resistance and clinical indications
- Cidofovir (vistide)
- Cidofovir: pharmacokinetics and toxicities
- Cidofovir: clinical indications and resistance
- Fomivirsen (vitravene)
- Influenza: orthmyxoviridae family
- Antiviral targets in influenza
- Anti-viral drugs for prevention/treatment of influenza
- Anti-influenza drugs: M2 inhibitors (1)
- Anti-influenza drugs: M2 inhibitors (2)
- Anti-influenza drugs: neuraminidase inhibitors
- Oseltamivir pharmacokinetics and toxicities
- Oseltamivir: clinical indications
- Oseltamivir vs. placebo in normal adults
- Time to symptom resolution in flu-infected patients
- Six week prevention trial: community flu outbreak
- Anti-hepatitis B drugs
- Lamivudine for HBV - toxicities and resistance
- Lamivudine for hepatitis B - clinical indications
- Adefovir dipivoxil (hepsera)
- Adefovir dipivoxil - pharmacokinetics, resistance
- Adefovir dipivoxil (hepsera) - clinical indications
- Entecavir: hepatitis B antiviral
- Entecavir continued...
- Resistance rates: lamivudine, hepsera, entecavir
- Recombinant interferon alpha
- Recombinant interferon
- Recombinant interferon - clinical indications (1)
- Recombinant interferon - clinical indications (2)
- Ribavirin: role in HCV infection
- Ribavirin
- Conclusions
Topics Covered
- Pharmacokinetics and clinical application of antiviral agents excluding antiretrovirals for HIV
- The therapeutic and prophylactic options for herpes infections including herpes simplex 1 and 2, varicella zoster and cytomegalovirus
- Therapeutic and prophylactic agents for influenza
- Approved agents for the treatment of hepatitis B and C
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Klotman, M. (2007, October 1). Non HIV antivirals [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 20, 2025, from https://doi.org/10.69645/EKTA2444.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Mary Klotman has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
